Clinical Study

Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

Table 4

Haplotype frequencies and comparison between Crohn’s patients with L1 ileum location, responders and nonresponders to infliximab therapy, in the chromosomal regions including (a) S100A9 and S100A8 genes (rs11205276, rs3014866, rs724781, and rs3006488); (b) G0S2 gene (rs4844486, rs1473683); (c) TNFAIP6 gene (rs11677200, rs2342910, rs3755480, and rs10432475); and (d) IL11 gene (rs1126760, rs1042506).
(a)

HaplotypeResponders (%)Nonresponders (%) value

GTCA3623.70.16
GCCA22.828.40.48
GCGA12.219.40.16
CTCA10.312.60.57
GTGG2.65.50.39
GTGA3.72.50.68
CCCA3.33.31.00
CCGA3.52.61.00
GCGG31.41.00
GCCG1.60.41.00

(b)

HaplotypeResponders (%)Nonresponders (%) value

CG71.575.80.54
AG25.7240.82
CT2.10.10.57

(c)

HaplotypeResponders (%)Nonresponders (%) value

CAGA39.427.10.14
TAGA20.224.40.56
TAAA14.924.10.13
TTGA16.110.70.37
TTGG9.513.70.47

(d)

HaplotypeResponders (%)Nonresponders (%) value

TT77.6830.40
CG1613.50.74
CT5.63.41.00